2012-09-18 08:06:44 - New Pharmaceuticals research report from Global Markets Direct is now available from Fast Market Research

Global Markets Direct's, 'Ulcerative Colitis - Pipeline Review, H2 2012', provides an overview of the Ulcerative Colitis therapeutic pipeline. This report provides information on the therapeutic development for Ulcerative Colitis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Ulcerative Colitis. 'Ulcerative Colitis - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the

indicated disease.


Full Report Details at
- www.fastmr.com/prod/463849_ulcerative_colitis_pipeline_review_h2 ..


Scope

* A snapshot of the global therapeutic scenario for Ulcerative Colitis.
* A review of the Ulcerative Colitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
* Coverage of products based on various stages of development ranging from discovery till registration stages.
* A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
* Coverage of the Ulcerative Colitis pipeline on the basis of route of administration and molecule type.
* Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
* Key discontinued pipeline projects.
* Latest news and deals relating to the products.

Reasons to buy

* Identify and understand important and diverse types of therapeutics under development for Ulcerative Colitis.
* Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
* Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
* Devise corrective measures for pipeline projects by understanding Ulcerative Colitis pipeline depth and focus of Ulcerative Colitis therapeutics.
* Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
* Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Keywords

Ulcerative Colitis Therapeutic Products under Development, Key Players in Ulcerative Colitis Therapeutics, Ulcerative Colitis Pipeline Overview, Ulcerative Colitis Pipeline, Ulcerative Colitis Pipeline Assessment

Partial Table of Contents:

Table of Contents
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Ulcerative Colitis Overview
Therapeutics Development
An Overview of Pipeline Products for Ulcerative Colitis
Ulcerative Colitis Therapeutics under Development by Companies
Ulcerative Colitis Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Ulcerative Colitis Therapeutics - Products under Development by Companies
Ulcerative Colitis Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Ulcerative Colitis Therapeutics Development
Bristol-Myers Squibb Company
Johnson & Johnson
Abbott Laboratories
Biogen Idec Inc.
Amgen Inc.
Athersys, Inc.
GlaxoSmithKline plc
Genentech, Inc.
MedImmune LLC
Euroscreen S.A.
Takeda Pharmaceutical Company Limited
BioLineRx, Ltd.
Celltrion, Inc.
Sylentis
Novartis AG
Pfizer Inc.
Zeria Pharmaceutical Co Ltd
4SC AG
Hollis-Eden Pharmaceuticals, Inc.
Karo Bio
Ore Pharmaceuticals Inc
Cosmo Pharmaceuticals S.p.A
Lexicon Pharmaceuticals, Inc.
Pluristem Therapeutics Inc.
Proximagen Neuroscience plc.
InDex Pharmaceuticals AB
Am-Pharma B.V.
Palau Pharma S.A
7TM Pharma A/S
Hutchison MediPharma Limited
Tillotts Pharma AG
Coronado Biosciences, Inc.
Txcell SA
Atlantic Pharmaceuticals, Inc.
China Medical System Holdings Limited
Drais Pharmaceuticals, Inc.
Giuliani S.p.A.
KYORIN Pharmaceutical Co., Ltd.
Synergy Pharmaceuticals, Inc.
NasVax Ltd.
Dr. Falk Pharma GmbH
Transcription Factor Therapeutics, Inc.
Altheus Therapeutics, Inc.
AesRx, LLC.
LIPID THERAPEUTICS GmbH
Sigmoid Pharma.
Ulcerative Colitis - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
Lialda - Drug Profile
RG7413 - Drug Profile
ASP3291 - Drug Profile
Tofacitinib - Drug Profile
Alicaforsen - Drug Profile

Full Table of Contents is available at:
-- www.fastmr.com/catalog/product.aspx?productid=463849&dt=t

About Global Markets Direct

Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality company and market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information. View more research from Global Markets Direct at www.fastmr.com/catalog/publishers.aspx?pubid=1033

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at www.fastmr.com or call us at 1.800.844.8156.